|
Video: What is a Stock Split?
|
|
Nkarta is a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Co. has two product candidates, NKX101 and NKX019. Both product candidates were generated using Co.'s NK cell engineering platform. NKX101 is designed to improve the power of innate NK biology to detect and kill cancerous cells. NKX019 is based on the ability to treat a variety of B-cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells, where CD19-targeted engineered NK cells, T cells and monoclonal antibodies have demonstrated clinical activity. According to our Nkarta stock split history records, Nkarta has had 0 splits. | |
|
Nkarta (NKTX) has 0 splits in our Nkarta stock split history database.
Looking at the Nkarta stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Nkarta shares, starting with a $10,000 purchase of NKTX, presented on a split-history-adjusted basis factoring in the complete Nkarta stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/13/2020 |
|
End date: |
04/17/2024 |
|
Start price/share: |
$38.52 |
|
End price/share: |
$7.86 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-79.60% |
|
Average Annual Total Return: |
-34.44% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,040.60 |
|
Years: |
3.76 |
|
|
|
|
|